Company Profile
89bio, Inc. Stock Price, News & Analysis
- Ticker:
- ETNB
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for ETNB.
Company overview
Business overview
89bio is a liver and metabolic disease company focused on MASH and related liver biology. Its story is driven by the possibility of creating a major liver-disease franchise.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, 89bio sits in specialty biopharma.
Business Model Characteristics
The business depends on clinical data, dose strategy, and whether the company can deliver a differentiated MASH profile.
Position Within the Biotechnology Landscape
89bio is one of the more closely watched liver-disease names because efficacy and safety can quickly change the story.
Future catalysts
89bio's catalysts are pegozafermin in MASH and severe hypertriglyceridemia, where the next data step can materially change the valuation. The company is still being judged on metabolic-disease execution.
Recent news
- 01
89bio, Inc. Announces Agreement to be Acquired by Roche
Source: 89bio, Inc.
- 02
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: 89bio, Inc.
- 03
89bio to Participate in Upcoming Investor Conferences
Source: 89bio, Inc.
- 04
89bio Reports Second Quarter 2025 Financial Results and Corporate Updates
Source: 89bio, Inc.
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does 89bio, Inc. do?
89bio is a liver and metabolic disease company focused on MASH and related liver biology. Its story is driven by the possibility of creating a major liver-disease franchise.
On which exchange is ETNB stock listed?
89bio, Inc. (ETNB) is associated with NASDAQ, United States, Biopharma.
Which therapeutic areas is 89bio, Inc. focused on?
89bio, Inc. is associated with metabolic disease based on its company overview and current catalyst commentary.
What future catalysts are investors watching for 89bio, Inc.?
89bio's catalysts are pegozafermin in MASH and severe hypertriglyceridemia, where the next data step can materially change the valuation. The company is still being judged on metabolic-disease execution.